Navigation Links
Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference

e drug development including demonstrating efficacy, development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our Annual Information Form underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Lorus Therapeutics Inc.'s recent press releases are available through the Company's website at www.lorusthera.com.

CONTACT: Lorus Therapeutics Inc., Dr. Saeid Babaei, (416) 798-1200 ext.490, ir@lorusthera.com

Ticker Symbol: (Toronto:LOR.),(AMEX:LRP)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:5/20/2008)...ice leads to 100% patient response ... /- BARRX Medical, Inc., a global,tec...day announced the,publication of two related Europ...r early esophageal cancer and pre-cancerous dyspla...n therapy with the HALO ablation,system. Barrett,s...
(Date:5/20/2008)...l/ -- Delcath Systems, Inc.,(Nasdaq: DCTH ) annou...tive,Officer, provided an update on enrollment num...rial today at a gathering of financial and healthc...w 5th Annual Global,Healthcare Conference., Mr. T... for the Phase,III clinical trial of the Company,s...
(Date:5/19/2008)... MORE SCIENCE SUPPORTING THE, THEORY THAT VACCINE...ewswire-USNewswire/ -- A primate model for autism,...s unveiled at the,International Meeting For Autism...scores the critical need for studies into vaccine ...n of autistic children. The National,Autism Associ...
(Date:5/19/2008)...ss Shionogi Phase 3 results on .../- InterMune, Inc.,(Nasdaq:...development of,pirfenidone for the treatment of id...st Track" designation from the U.S. Food and Drug,...that the FDA reserves for,a drug intended to treat...
Breaking Medicine Technology:Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination 2Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination 3Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited 2Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited 3UPDATE: Infant Primates Given Vaccines on U.S. Children's Immunization Schedule Develop Behavioral Symptoms of Autism 2InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA 2InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA 3Global Health and Business Leaders Announce 36 Month Effort to Expand Malaria Control in Africa 3B 3 5 Million Lives Could be Saved in Five Years Stu 10123 1Global Health and Business Leaders Announce 36 Month Effort to Expand Malaria Control in Africa 3B 3 5 Million Lives Could be Saved in Five Years Stu 10123 2Global Health and Business Leaders Announce 36 Month Effort to Expand Malaria Control in Africa 3B 3 5 Million Lives Could be Saved in Five Years Stu 10123 3Global Health and Business Leaders Announce 36 Month Effort to Expand Malaria Control in Africa 3B 3 5 Million Lives Could be Saved in Five Years Stu 10123 4Metabolic syndrome affects nearly 1 in 10 US teens 10120 1Metabolic syndrome affects nearly 1 in 10 US teens 10120 2Metabolic syndrome affects nearly 1 in 10 US teens 10120 3NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results 10117 1NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results 10117 2NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results 10117 3Bill Germanakos and Hollie Self Bring The Biggest Loser Million Pound Tour Presented by MSN to Arizona Mills Mall 10114 1Bill Germanakos and Hollie Self Bring The Biggest Loser Million Pound Tour Presented by MSN to Arizona Mills Mall 10114 2
...ind these data reassuring", PHILADELPHIA, June 05,...id today that findings from an interim analysis,of...mes and,Regulation of glycemia in Diabetes), a pro...etermine cardiovascular outcomes in more,than 4,40...ence to,the overall cardiovascular safety profile ...
...--Jun 5, 2007 - Elixir,Pharmaceuticals, Inc., anno...n antagonism as a potential method for regulating,...ood glucose. The,data were presented in poster ses... Annual Meeting, being held in Toronto,Canada. El...at and,prevent metabolic disease, as well as preve...
Other Medicine Technology:Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 2Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 3Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 4Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 5Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 2Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 3Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 4
(Date:5/20/2008)... Survey also reveals less than 5% trust magazines...RK, May 20 /PRNewswire-USNewswire/ -- The Physicia...jectablesafety.org ) and the health and,beauty com...day released,findings of a joint survey reporting ...ties are safe, and only 58% of consumers feel FDA ...
(Date:5/20/2008)... CHELMSFORD, Mass., May 20 /PRNewswire-FirstCall/...), a leading provider of specialized,high-perform..., and signal,processing applications, announced th...any,s business on Thursday, May 29, 2008 at the Co...ference. The Conference will be,held at the New Yo...
(Date:5/20/2008)...To advance underdeveloped approaches to designing ...f Allergy and Infectious Diseases (NIAID), part of... new program to foster the study of B cells, immun...ity to neutralize HIV. The $15.6 million, five-yea...c foundation of HIV vaccine research through a net...
(Date:5/20/2008)... CHAPEL HILL, N.C., May 20 /PRNewswire/ -- New re...isition integration and competitive,intelligence d...able in the,Best Practice Database, an online rese... firm Best Practices, LLC., To review sample key ...,landing page with links to each study at this add...
Breaking Medicine News(10 mins):Health News:New Survey Suggests That Consumers Are Naive to the Risk of Botox Parties and the Importance of FDA Approval for Cosmetic Injectables 2Health News:New Survey Suggests That Consumers Are Naive to the Risk of Botox Parties and the Importance of FDA Approval for Cosmetic Injectables 3Health News:New Survey Suggests That Consumers Are Naive to the Risk of Botox Parties and the Importance of FDA Approval for Cosmetic Injectables 4Health News:Mercury Computer Systems to Present at the Cowen and Company 20/20 Technology-Media-Telecom Conference on May 29, 2008 2Health News:NIAID to advance B-cell approach to HIV vaccines 2Health News:NIAID to advance B-cell approach to HIV vaccines 3Health News:Best Practice Database Adds Research on Merger Integration and Competitive Intelligence 2
... a patient’s specific culture into consideration c...e incidence of diabetes-related complications over...er management results in reduced long-term complic...utation and nerve damage,” said lead researcher To...
...an, who was rushed to a city hospital here Sunday ...er and recovering from severe exertion, hospital s...but will be kept under observation for the next tw...ital dean N. Trivedi. Saif, 36, was rushed to Li...
...ng Victorian hospital staff could be putting the h...n and control experts. A study published in the ...n half of Victorian health workers in public hospi...ugh the vaccine is provided free through the natio...
...ins is under pressure- he is asked to respond to a... Muckamore Abbey Hospital, which ‘cares’ for peopl...ckamore Abbey Hospital, which houses around 100 ad...der police investigation. The issue came about wh...
Other Medicine News:Health News:Culturally Specific Diabetes Management Helps Low-Income Patients 2
Stainless steel threaded Steinman Pins available in point types A,D, E, and F.
Swanson Finger Pins are stainless steel and available in one length and three diameters.
Instera pins are sterile packaged and are available in 0.89, 1.1, 1.5, and 2.0mm diameters.
...ng Jet-X Pin products are available: , 5mm x 30mm ...6 Cannulated H-Pin , 5mm x 50mm Traction Pin ...SST Half Pin , TI 5mm Half Pin , TI 5mm x ...in , TI Half Pin , TiN 5 x 40, 1.6 Cann ...
Medicine Products: